Clinical Trial Update: BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating BCMA-CD19 CCAR T cell therapy for refractory immune thrombocytopenia associated with autoimmune diseases, sponsored by iC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• BCMA-CD19 CCAR T cells

Snippet

Sponsor: iCell Gene Therapeutics | Conditions: Refractory Immune Cytopenia | Phase 1 | Status: RECRUITING